At UCLA's Broad Center of Regenerative Medicine and Stem Cell Research, scientists have discovered that creatine—the humble supplement favored by athletes and bodybuilders—can supercharge dendritic cells, the specialized immune soldiers that activate the body's most potent cancer fighters.
The finding, published in iScience, emerges from research conducted in mouse models and human cells, and it addresses a stubborn limitation in modern cancer treatment. Most approved cancer immunotherapies work by targeting killer T cells directly, yet only 20–40% of patients respond to them. This is where dendritic cells come in. These immune cells capture tumor fragments and direct killer T cells to attack, making them the critical infrastructure that modern immunotherapies depend on. By boosting dendritic cells themselves, researchers may finally extend the promise of immunotherapy to the patients currently left behind.
Lili Yang, a professor of microbiology, immunology and molecular genetics who led the study, explains the broader vision: "Creatine doesn't just help the T cells fighting cancer—it also energizes the entire infrastructure that supports and guides them." The team began by examining metabolic genes active in dendritic cells that had infiltrated tumors in mice. They discovered that the gene encoding the creatine transporter—a protein that pulls creatine inside cells—was markedly elevated in dendritic cells inside tumors compared to those in healthy tissue.
When the researchers engineered dendritic cells to lack the creatine transporter entirely, the results were striking. These cells showed impaired survival, reduced activation, and a weakened ability to prime T cells to mount a response against tumors. When creatine-deficient dendritic cells were grown alongside T cells in the lab, those T cells divided less and produced fewer signaling molecules needed to fight cancer. The message was clear: creatine mattered.
The opposite experiment proved equally revealing. Giving daily creatine injections to mouse models of melanoma significantly slowed tumor growth and boosted both the abundance and activation of tumor-infiltrating dendritic cells. Creatine-treated dendritic cells also produced higher levels of chemical signals that draw additional immune cells into the tumor—amplifying the immune response across the board. Using metabolomics analyses, the team found that creatine supplementation raised intracellular ATP levels in dendritic cells—ATP being the energy currency cells use to power virtually every function. Like a battery storing and releasing excess energy on demand, creatine helps dendritic cells maintain stable energy levels even when competing with fast-growing tumor cells for nutrients.
The implications extend beyond mice. When the researchers tested creatine's effects on human dendritic cells, creatine treatment enhanced the activation of human monocyte-derived dendritic cells—cells often used in dendritic cell cancer vaccines—and improved their ability to stimulate human T cells against a cancer-associated target. The findings suggest that incorporating creatine during the manufacturing of dendritic cell vaccines may boost their therapeutic potency.
Looking forward, Yang envisions creatine working in two complementary ways: as a supplement to enhance the immune response of patients already receiving immunotherapy, and as a tool to improve the quality of dendritic cell-based vaccines before they are administered. For the millions of cancer patients for whom current immunotherapies fall short, this simple molecule may open an entirely new door.